Retraction Notice: The Role of ILC2s in Enhancing Glucose Metabolism

Overview

The article discussing the role of ILC2s in glucose metabolism has been retracted due to concerns about data integrity. The authors did not provide satisfactory explanations during the investigation process.

Background

Retractions in scientific literature are significant. This particular study aimed to explore the relationship between ILC2s and glucose metabolism. Understanding the integrity of research findings is crucial.

Data Highlights

No numerical or trial data is provided in the retraction notice.

Key Findings

• The original research article was retracted due to integrity concerns regarding images and data.
• The authors failed to satisfactorily address these concerns during the investigation.
• The retraction was approved by the Chief Editors of Frontiers in Immunology.
• The retraction notice was published on July 17, 2026.
• The article was originally published in 2021 and aimed to investigate ILC2s' role in glucose metabolism.

Clinical Implications

Healthcare professionals should be aware of the retraction.

Conclusion

The retraction of this article highlights the issue of data integrity in scientific research.

Related Resources & Content

1. Frontiers Editorial Office, Frontiers in Immunology, 2026 -- Retraction: ILC2s improve glucose metabolism through the control of saturated fatty acid absorption within visceral fat
2. The Journal of Clinical Endocrinology & Metabolism — Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study
3. The Journal of Clinical Endocrinology & Metabolism — The Role of Mesenteric Fat Mass in Visceral Fat Accumulation and Glucose Metabolism
4. The Journal of Clinical Endocrinology & Metabolism — Association of Fetuin B with Cytokine/Chemokine Activity and Insulin Pathways in Human Adipose Tissue and Plasma
5. The Journal of Clinical Endocrinology & Metabolism — Association of Liver Fat Accumulation with Elevated Insulin Secretion Regardless of Total, Visceral, and Pancreatic Fat Levels
6. Summary of Revisions: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
7. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity | New England Journal of Medicine
8. Dysfunctional adipose tissue–lymphatic crosstalk in obesity | Nature Reviews Endocrinology